AVDL vs. MRUS, CYTK, VKTX, TGTX, KRYS, ACAD, PCVX, AAPG, ACLX, and ADMA
Should you be buying Avadel Pharmaceuticals stock or one of its competitors? The main competitors of Avadel Pharmaceuticals include Merus (MRUS), Cytokinetics (CYTK), Viking Therapeutics (VKTX), TG Therapeutics (TGTX), Krystal Biotech (KRYS), ACADIA Pharmaceuticals (ACAD), Vaxcyte (PCVX), Ascentage Pharma Group International (AAPG), Arcellx (ACLX), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry.
Avadel Pharmaceuticals vs. Its Competitors
Avadel Pharmaceuticals (NASDAQ:AVDL) and Merus (NASDAQ:MRUS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.
Avadel Pharmaceuticals has higher revenue and earnings than Merus. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Merus, indicating that it is currently the more affordable of the two stocks.
Avadel Pharmaceuticals presently has a consensus target price of $19.67, indicating a potential upside of 32.44%. Merus has a consensus target price of $88.75, indicating a potential upside of 32.74%. Given Merus' higher probable upside, analysts clearly believe Merus is more favorable than Avadel Pharmaceuticals.
Avadel Pharmaceuticals has a net margin of -1.32% compared to Merus' net margin of -685.64%. Avadel Pharmaceuticals' return on equity of -3.73% beat Merus' return on equity.
69.2% of Avadel Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.1% of Merus shares are owned by institutional investors. 5.2% of Avadel Pharmaceuticals shares are owned by insiders. Comparatively, 3.7% of Merus shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Avadel Pharmaceuticals has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500. Comparatively, Merus has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500.
In the previous week, Merus had 8 more articles in the media than Avadel Pharmaceuticals. MarketBeat recorded 11 mentions for Merus and 3 mentions for Avadel Pharmaceuticals. Merus' average media sentiment score of 1.26 beat Avadel Pharmaceuticals' score of 0.78 indicating that Merus is being referred to more favorably in the news media.
Summary
Avadel Pharmaceuticals beats Merus on 9 of the 16 factors compared between the two stocks.
Get Avadel Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVDL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AVDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avadel Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:AVDL) was last updated on 8/27/2025 by MarketBeat.com Staff
MarketBeat All Access